Development of a multimeric self-amplifying RNA rotavirus vaccine

轮状病毒疫苗效力的提高将加强对低收入国家中轮状病毒疾病的保护，在这些地方，目前获得许可的轮状病毒疫苗的效力较低，但疾病负担最大。降低每剂疫苗的成本并简化疫苗生产(由于使用合成SANA)将减少对全球疫苗和免疫联盟的财政依赖，并增加向资源有限的国家转让技术以控制其疫苗需求的可能性。

Improvement on rotavirus vaccine efficacy will increase protection against rotavirus disease in LMICs where efficacy from the currently licensed rotavirus vaccines is lower but burden of disease is greatest. A decrease in the cost per dose and streamlining vaccine manufacturing (due to the use of synthetic saRNA) will decrease financial dependency on GAVI and increase the possibility for technology transfer to resource limited countries to take control of their vaccine requirements.